

# JC14 Rec'd PCT/PTO 0 4 JAN

19603/2595 (CRF D-2400)

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Hempstead et al.

Serial No

09/830,520 based on PCT/US99/25365

Examiner: Unknown

Cnfrm No

9715

Art Unit: 1642

Filed

October 28, 1999

RECEIVED

For

METHODS FOR REGULATING

JUN 1 7 2002

ANGIOGENESIS AND VASCULAR INTEGRITY USING TRK RECEPTOR

**TECH CENTER 1600/2900** 

**LIGANDS** 

## REQUEST FOR CORRECTED FILING RECEIPT

**Assistant Commissioner for Patents** Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Dear Sir:

Applicants hereby request a corrected filing receipt for the aboveidentified application. On the enclosed copy of the official filing receipt, there is a typographical error in the name of the third inventor. The third inventor's name reads "Shahin Rafil" but should read "Shahin Rafii". A copy of the signed combined declaration and power of attorney as filed is enclosed herewith.

Since Applicants are not responsible for this error, no fee is enclosed.

Respectfully submitted,

Dated: October 18, 2001

rgia Eyans

Registration No. 44,597

Nixon Peabody LLP

Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (716) 263-1672 Facsimile: (716) 263-1600 Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231,



JUN 1 7 2002



JAN 0 4 2002

### United States Patent and Trademark Office

### **TECH CENTER 1600/2900**

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

www.uspto.gov APPLICATION NUMBER FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS 09/830.520 07/20/2001 1642 1001 19603/2595 10 8

**CONFIRMATION NO. 9715** 

FILING RECEIPT

\*OC000000006498467\*

Nixon Peabody Clinton Square PO Box 31051 Rochester, NY 14603

Date Mailed: 08/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Barbara L. Hempstead, New York, NY;
Rosemary Kraemer, Brooklyn, NY;
Shahin Rafiil Great Neck, NY;
Phi Wiegn, New York, NY;
Michael J. Donovan, Brookline, MA:

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/25365 10/28/1999 WHICH CLAIMS BENEFIT OF 60/119,994 02/12/1999 WHICH CLAIMS BENEFIT OF 60/105,928 10/28/1998

Foreign Applications

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

**Preliminary Class** 

514

Data entry by : ORDENEZ, MARTA

Team : OIPE

Date: 08/30/2001

I KERKETI KAN ERRIT ETKET MUDI KERET TEMI ERRIS TAKA KRIBE MUNI BUDUK KANDI KERUK BERUK BERUK BURUK BUTUK SETAK BUDUK BERUK BERUK BURUK BUDUK BUDUK BERUK BERUK BURUK B BURUK BURUK



#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231